Wan-Jin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wan-Jin Chen has a total of 536 co-authors. Here are the top co-authors by number of shared publications:
Ning Wang
Department of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University , Fuzhou
27 shared publications- Ning Wang
Department of Neurology, Fujian Institute of Neurology The First Affiliated Hospital, Fujian Medical University Fuzhou China
26 shared publications - Ying Fu
Department of Neurology and Institute of Neurology of First Affiliated Hospital Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University Fuzhou China
14 shared publications Xin-Xin Guo
Department of Neurology, The First Affiliated Hospital, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou 350005, China
13 shared publicationsChong Wang
Department of Neurology, The First Affiliated Hospital, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou 350005, China
12 shared publicationsMiao Zhao
Department of Neurology, the First Affiliated Hospital, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou 350005, China; Department of Neurology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350212, China
12 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Stage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3
Objective: Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been well characterized, less is known about non‐motor and imaging‐based features across different disease stages. This study aimed to characterize stage‐specific patterns of non‐motor and imaging biomarkers in SCA3. Methods: This cross‐observational study included 229 patients with SCA3 and 104 age‐ and sex‐matched healthy controls from the Organization for Southeast China for cerebellar ataxia research. Non‐motor symptoms were assessed using a battery of neuropsychological tests. Brain volume loss was assessed by 3.0‐Tesla MRI with regions‐of‐interest (ROI)‐based volumetric analysis. Neuroinflammation was quantified in vivo using translocator protein positron emission tomography (TSPO‐PET) with the 18 F‐DPA‐714 radioligand. Additive regression models were fitted to evaluate the cross‐sectional associations between biomarkers and disease stages. Receiver operating curve (ROC) analyses were applied to estimate the discriminative ability of the candidate biomarkers. Results: Non‐motor symptoms, including cognitive functions, anxiety, fatigue, depression, and sleep quality, declined after ataxia onset in SCA3. Volume loss in the brainstem and ventral diencephalon diverged from normal controls at 0.7 and 0.2 years before ataxia onset, respectively. Correspondingly, the TSPO signal in the brainstem and ventral diencephalon increased and deviated from normal throughout the disease course. Interpretation: Our findings propose a staging model of SCA3 that includes a biomarker stage characterized by multidimensional objective indicators of neurodegeneration and neuroinflammation from pre‐ataxia to ataxia onset. Trial Registration: ClinicalTrials.gov identifier: NCT04010214
- 13 October 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Open AccessStage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3
Objective: Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been well characterized, less is known about non‐motor and imaging‐based features across different disease stages. This study aimed to characterize stage‐specific patterns of non‐motor and imaging biomarkers in SCA3. Methods: This cross‐observational study included 229 patients with SCA3 and 104 age‐ and sex‐matched healthy controls from the Organization for Southeast China for cerebellar ataxia research. Non‐motor symptoms were assessed using a battery of neuropsychological tests. Brain volume loss was assessed by 3.0‐Tesla MRI with regions‐of‐interest (ROI)‐based volumetric analysis. Neuroinflammation was quantified in vivo using translocator protein positron emission tomography (TSPO‐PET) with the 18 F‐DPA‐714 radioligand. Additive regression models were fitted to evaluate the cross‐sectional associations between biomarkers and disease stages. Receiver operating curve (ROC) analyses were applied to estimate the discriminative ability of the candidate biomarkers. Results: Non‐motor symptoms, including cognitive functions, anxiety, fatigue, depression, and sleep quality, declined after ataxia onset in SCA3. Volume loss in the brainstem and ventral diencephalon diverged from normal controls at 0.7 and 0.2 years before ataxia onset, respectively. Correspondingly, the TSPO signal in the brainstem and ventral diencephalon increased and deviated from normal throughout the disease course. Interpretation: Our findings propose a staging model of SCA3 that includes a biomarker stage characterized by multidimensional objective indicators of neurodegeneration and neuroinflammation from pre‐ataxia to ataxia onset. Trial Registration: ClinicalTrials.gov identifier: NCT04010214
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2) , e200360
Precision Diagnosis of Wilson Disease Using a MultiGene Panel
Background and ObjectivesWilson disease (WD) is an autosomal recessive disorder of copper metabolism. Conventional genetic diagnostics are low-throughput and may miss intronic, structural, or pheno...
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2) , e200360
Open AccessPrecision Diagnosis of Wilson Disease Using a MultiGene Panel
Background and ObjectivesWilson disease (WD) is an autosomal recessive disorder of copper metabolism. Conventional genetic diagnostics are low-throughput and may miss intronic, structural, or pheno...
- 9 March 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 186, 2111735
Neurophysiological abnormalities of attentional deficits in Wilson’s disease using visual oddball paradigm
- 9 March 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 186, 2111735
Neurophysiological abnormalities of attentional deficits in Wilson’s disease using visual oddball paradigm
- Open Access
- 23 February 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (8) , 1673-1685
Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression
Background: Skewed myelopoiesis in the bone marrow has been identified as a key driver of multiple sclerosis (MS) progression. Interestingly, SARS‐CoV‐2 infection, which has a severe impact on MS patients, can also induce similar skewed myelopoiesis. This shared phenotype raises the question of whether a common mechanism underlies the skewed myelopoiesis in both diseases. Previous studies in mice have demonstrated that the dysregulation of endogenous retroelements (EREs) in HSPCs leads to skewed myelopoiesis. Building on this, we sought to determine whether ERE dysregulation contributes to the skewed myelopoiesis observed in MS and after COVID‐19, which remains challenging. Methods: We undertook a joint investigation of two public single‐cell/nuclei cohorts respectively representing MS and following COVID‐19. Both cohorts were processed through an identical bioinformatic pipeline to ensure comparable assessment of gene and ERE expression. Results: We observed enhanced myelopoiesis in the bone marrow of MS patients compared to healthy controls, along with downregulation of the ERE repressor H3.3 and concomitant EREs overexpression. Notably, a similar epigenetic and transcript feature was found in post‐COVID‐19 individuals. Conclusion: The H3.3 low /ERE high signature may not only explain the common skewed myelopoiesis in MS and post‐COVID‐19 conditions, but also provide a mechanistic link between infection and the innate immune reprogramming that drives MS progression. This offers a novel therapeutic insight for MS.
- 23 February 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (8) , 1673-1685
Open AccessInnate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression
Background: Skewed myelopoiesis in the bone marrow has been identified as a key driver of multiple sclerosis (MS) progression. Interestingly, SARS‐CoV‐2 infection, which has a severe impact on MS patients, can also induce similar skewed myelopoiesis. This shared phenotype raises the question of whether a common mechanism underlies the skewed myelopoiesis in both diseases. Previous studies in mice have demonstrated that the dysregulation of endogenous retroelements (EREs) in HSPCs leads to skewed myelopoiesis. Building on this, we sought to determine whether ERE dysregulation contributes to the skewed myelopoiesis observed in MS and after COVID‐19, which remains challenging. Methods: We undertook a joint investigation of two public single‐cell/nuclei cohorts respectively representing MS and following COVID‐19. Both cohorts were processed through an identical bioinformatic pipeline to ensure comparable assessment of gene and ERE expression. Results: We observed enhanced myelopoiesis in the bone marrow of MS patients compared to healthy controls, along with downregulation of the ERE repressor H3.3 and concomitant EREs overexpression. Notably, a similar epigenetic and transcript feature was found in post‐COVID‐19 individuals. Conclusion: The H3.3 low /ERE high signature may not only explain the common skewed myelopoiesis in MS and post‐COVID‐19 conditions, but also provide a mechanistic link between infection and the innate immune reprogramming that drives MS progression. This offers a novel therapeutic insight for MS.
- Open Access
- 30 January 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 184, 2111517
Spatiotemporal abnormalities in brain networks as a signature of neurological damage in Wilson’s disease
- 30 January 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 184, 2111517
Open AccessSpatiotemporal abnormalities in brain networks as a signature of neurological damage in Wilson’s disease
- 4 December 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (2) , 315-336
Primary Brain Calcification: An International Consensus on Nomenclature, Diagnosis, Evaluation, and Management
Our understanding of primary brain calcification (PBC) has accelerated with the identification of seven causative genes over the past 13 years, vastly expanding knowledge of the molecular underpinnings of this disorder. Despite this progress, a lack of standardized clinical definitions, variable presentations, and heterogeneous calcification patterns has perpetuated inconsistencies in diagnosis and patient care. To address these challenges, an international expert panel undertook a comprehensive process—combining systematic literature review, virtual and in‐person expert discussions, and iterative Delphi consensus questionnaires—to develop unified recommendations. These consensus guidelines encompass terminology, diagnostic criteria, neuroimaging protocols, clinical evaluation standards, genetic testing approaches, and management strategies. Notably, PBC is recommended as the clinical standard, with new diagnostic criteria, including the use of a computed tomography–based total calcification score and a three‐tiered diagnostic algorithm (possible, probable, definite PBC). A systematic review of 27 symptoms and signs identified 19 as most closely linked with PBC, guiding more focused clinical assessment. Recommendations strongly support comprehensive next‐generation sequencing for genetic testing, favoring whole genome over exome or targeted panels to maximize diagnostic yield. Multidisciplinary management priorities are outlined in four key principles centering on individualized care, symptom relief, genetic counseling, and ongoing monitoring. Widespread adoption of these unified guidelines will facilitate consistent diagnosis, enable comparative international data collection, and lay the groundwork for large‐scale collaborative research—including future randomized controlled trials of symptomatic and disease‐modifying PBC therapies. This consensus fosters clarity and consistency, creating a framework for improved patient care and scientific discovery. © 2025 International Parkinson and Movement Disorder Society.
- 4 December 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (2) , 315-336
Primary Brain Calcification: An International Consensus on Nomenclature, Diagnosis, Evaluation, and Management
Our understanding of primary brain calcification (PBC) has accelerated with the identification of seven causative genes over the past 13 years, vastly expanding knowledge of the molecular underpinnings of this disorder. Despite this progress, a lack of standardized clinical definitions, variable presentations, and heterogeneous calcification patterns has perpetuated inconsistencies in diagnosis and patient care. To address these challenges, an international expert panel undertook a comprehensive process—combining systematic literature review, virtual and in‐person expert discussions, and iterative Delphi consensus questionnaires—to develop unified recommendations. These consensus guidelines encompass terminology, diagnostic criteria, neuroimaging protocols, clinical evaluation standards, genetic testing approaches, and management strategies. Notably, PBC is recommended as the clinical standard, with new diagnostic criteria, including the use of a computed tomography–based total calcification score and a three‐tiered diagnostic algorithm (possible, probable, definite PBC). A systematic review of 27 symptoms and signs identified 19 as most closely linked with PBC, guiding more focused clinical assessment. Recommendations strongly support comprehensive next‐generation sequencing for genetic testing, favoring whole genome over exome or targeted panels to maximize diagnostic yield. Multidisciplinary management priorities are outlined in four key principles centering on individualized care, symptom relief, genetic counseling, and ongoing monitoring. Widespread adoption of these unified guidelines will facilitate consistent diagnosis, enable comparative international data collection, and lay the groundwork for large‐scale collaborative research—including future randomized controlled trials of symptomatic and disease‐modifying PBC therapies. This consensus fosters clarity and consistency, creating a framework for improved patient care and scientific discovery. © 2025 International Parkinson and Movement Disorder Society.
- 30 August 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 215, 107073
Corrigendum to “Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis”
- 30 August 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 215, 107073
Corrigendum to “Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis”
- Open Access
- 15 August 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 214, 107059
Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis
- 15 August 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 214, 107059
Open AccessBiomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis
- 24 June 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (4) , 750-761
Clinical and Genetic Findings in a Chinese Cohort of Dentatorubral–Pallidoluysian Atrophy Patients
Objective: Dentatorubral–pallidoluysian atrophy (DRPLA) is a rare, inherited neurodegenerative disorder caused by the expansion of cytosine–adenine–guanine repeats in ATN1 . Most studies on DRPLA to date are limited to case reports. We aimed to provide a comprehensive summary of the clinical, genetic, biological, and magnetic resonance imaging characteristics of DRPLA using cross‐sectional baseline data. Methods: This is a cross‐sectional observational cohort study. We used an extensive battery of assessments, included clinical phenotypes, genotypes, cognitive performance, biological markers, and magnetic resonance imaging characteristics. Results: We enrolled 116 DRPLA patients, including 96 manifest patients and 20 prodromal patients. We identified a previously unreported ATN1 haplotype consisting of 8 single‐nucleotide polymorphisms. Cognitive assessments revealed that 51 manifest patients (96%) and 4 prodromal patients (29%) scored P < 0.001) and healthy controls ( P < 0.001). Magnetic resonance imaging findings revealed widespread gray matter loss across the whole brain in manifest patients, whereas prodromal patients showed gray matter loss localized to the bilateral cerebellar hemispheres. Interpretation: This is the first DRPLA cohort study to comprehensively report clinical, genetic, cognitive, imaging, and plasma neurofilament light data. This study provides robust data to enhance our understanding of the overall features of DRPLA. We also propose clear definitions for the preclinical stage of DRPLA, and demonstrate the high diagnostic utility of plasma neurofilament light as a biomarker. ANN NEUROL 2025;98:750–761
- 24 June 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (4) , 750-761
Clinical and Genetic Findings in a Chinese Cohort of Dentatorubral–Pallidoluysian Atrophy Patients
Objective: Dentatorubral–pallidoluysian atrophy (DRPLA) is a rare, inherited neurodegenerative disorder caused by the expansion of cytosine–adenine–guanine repeats in ATN1 . Most studies on DRPLA to date are limited to case reports. We aimed to provide a comprehensive summary of the clinical, genetic, biological, and magnetic resonance imaging characteristics of DRPLA using cross‐sectional baseline data. Methods: This is a cross‐sectional observational cohort study. We used an extensive battery of assessments, included clinical phenotypes, genotypes, cognitive performance, biological markers, and magnetic resonance imaging characteristics. Results: We enrolled 116 DRPLA patients, including 96 manifest patients and 20 prodromal patients. We identified a previously unreported ATN1 haplotype consisting of 8 single‐nucleotide polymorphisms. Cognitive assessments revealed that 51 manifest patients (96%) and 4 prodromal patients (29%) scored P < 0.001) and healthy controls ( P < 0.001). Magnetic resonance imaging findings revealed widespread gray matter loss across the whole brain in manifest patients, whereas prodromal patients showed gray matter loss localized to the bilateral cerebellar hemispheres. Interpretation: This is the first DRPLA cohort study to comprehensively report clinical, genetic, cognitive, imaging, and plasma neurofilament light data. This study provides robust data to enhance our understanding of the overall features of DRPLA. We also propose clear definitions for the preclinical stage of DRPLA, and demonstrate the high diagnostic utility of plasma neurofilament light as a biomarker. ANN NEUROL 2025;98:750–761
- 14 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (798) , eadv4656
Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy
Neurological disorders with onset before or at birth are a leading cause of morbidity and mortality in infants and children. Prenatal treatment has the potential to reduce or prevent irreversible neuronal loss and facilitate normal neurodevelopment. We hypothesized that antisense oligonucleotides (ASOs) delivered to the amniotic fluid by intra-amniotic (IA) injection could safely distribute to the fetal central nervous system (CNS) and provide therapeutic benefit in the motor neuron disease spinal muscular atrophy (SMA), caused by mutations of the survival of motor neuron 1 gene ( SMN1 ), leading to deficiency of SMN protein. Although the splice-switching ASO nusinersen ameliorates SMA when delivered postnatally, substantial deficits can remain in severely affected infants. Here, IA injection of ASOs into two mouse models of severe SMA increased SMN expression in the CNS. In SMAΔ7 mice, which manifest pathology in utero, prenatal treatment improved motor neuron numbers, motor axon development, motor behavioral tests, and survival when compared with those in mice treated postnatally (between P1 and P3). To assess the feasibility of prenatal treatment in a large-animal model, ASOs were delivered midgestation to fetal sheep by IA or intracranial injection. ASOs delivered by IA injection distributed to the spinal cord at therapeutic concentrations and to multiple peripheral tissues without evidence of substantial toxicity to the fetus or mother. These data demonstrated that IA delivery of ASOs holds potential as a minimally invasive approach for prenatal treatment of SMA and possibly other severe, early-onset neurological disorders.
- 14 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (798) , eadv4656
Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy
Neurological disorders with onset before or at birth are a leading cause of morbidity and mortality in infants and children. Prenatal treatment has the potential to reduce or prevent irreversible neuronal loss and facilitate normal neurodevelopment. We hypothesized that antisense oligonucleotides (ASOs) delivered to the amniotic fluid by intra-amniotic (IA) injection could safely distribute to the fetal central nervous system (CNS) and provide therapeutic benefit in the motor neuron disease spinal muscular atrophy (SMA), caused by mutations of the survival of motor neuron 1 gene ( SMN1 ), leading to deficiency of SMN protein. Although the splice-switching ASO nusinersen ameliorates SMA when delivered postnatally, substantial deficits can remain in severely affected infants. Here, IA injection of ASOs into two mouse models of severe SMA increased SMN expression in the CNS. In SMAΔ7 mice, which manifest pathology in utero, prenatal treatment improved motor neuron numbers, motor axon development, motor behavioral tests, and survival when compared with those in mice treated postnatally (between P1 and P3). To assess the feasibility of prenatal treatment in a large-animal model, ASOs were delivered midgestation to fetal sheep by IA or intracranial injection. ASOs delivered by IA injection distributed to the spinal cord at therapeutic concentrations and to multiple peripheral tissues without evidence of substantial toxicity to the fetus or mother. These data demonstrated that IA delivery of ASOs holds potential as a minimally invasive approach for prenatal treatment of SMA and possibly other severe, early-onset neurological disorders.